The Ovarian Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Ovarian Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ovarian Disease. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Ovarian Disease - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ovarian Disease and features dormant and discontinued products.

GlobalData tracks 34 drugs in development for Ovarian Disease by 32 companies/universities/institutes. The top development phase for Ovarian Disease is preclinical with 17 drugs in that stage. The Ovarian Disease pipeline has 30 drugs in development by companies and four by universities/ institutes. Some of the companies in the Ovarian Disease pipeline products market are: CHA Biotech, Celmatix and Besins Healthcare.

The key targets in the Ovarian Disease pipeline products market include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31), Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR), and Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1).

The key mechanisms of action in the Ovarian Disease pipeline product include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) Activator with two drugs in Phase I. The Ovarian Disease pipeline products include nine routes of administration with the top ROA being Oral and eight key molecule types in the Ovarian Disease pipeline products market including Cell Therapy, and Small Molecule.

Ovarian Disease overview

Ovarian disease is a term for various conditions that affect the ovaries, which are the female reproductive organs that produce eggs and hormones. The most common ovarian diseases include polycystic ovary syndrome (PCOS), a hormonal disorder that causes irregular periods, excess androgen, and multiple cysts on the ovaries. PCOS can affect fertility and increase the risk of diabetes and heart disease. Another is ovarian cysts, fluid-filled sacs that develop on or in the ovaries. Most ovarian cysts are harmless and go away on their own, but some can cause pain, bleeding, or rupture. Ovarian cysts can be caused by hormonal imbalances, endometriosis, pregnancy, or other factors. Ovarian cancer is a type of cancer that starts in the ovaries or the fallopian tubes. Ovarian cancer can spread to other organs and cause various symptoms, such as abdominal bloating, pelvic pain, weight loss, or abnormal bleeding. Ovarian cancer can be treated with surgery, chemotherapy, or targeted therapy. Ovarian germ cell tumors are a rare type of tumor that originates from the cells that produce eggs. Ovarian germ cell tumors can be benign or malignant and usually affect young women or girls. Ovarian germ cell tumors can cause hormonal changes, abdominal pain, or a palpable mass. Ovarian germ cell tumors can be treated with surgery, chemotherapy, or radiation therapy.

For a complete picture of Ovarian Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.